NCT06714721 Magnetic Stimulation of Diaphragm in Chronic Obstructive Pulmonary Disease
| NCT ID | NCT06714721 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ankara University |
| Condition | Chronic Obstructive Pulmonary Disease (COPD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 66 participants |
| Start Date | 2023-08-23 |
| Primary Completion | 2025-08-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 66 participants in total. It began in 2023-08-23 with a primary completion date of 2025-08-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation and respiratory symptoms due to airway and/or alveolar deterioration caused by severe exposure to harmful particles or gases and host factors. Exercise intolerance and decreased functional capacity develop as a result of the disorders that occur in COPD. The aim of this study is to evaluate the effectiveness of repetitive peripheral magnetic stimulation (rPMS), an easy and inexpensive method to increase diaphragm strength as an adjunct to the pulmonary rehabilitation (PR) program applied in COPD, and to investigate the effect of this method on exercise capacity, diaphragm muscle thickness and symptoms.
Eligibility Criteria
Inclusion Criteria: 1. Having been diagnosed with COPD at least 6 months ago 2. Being over 18 years of age 3. Having the cognitive ability to understand the questions and fill out the questionnaires 4. Agreeing to participate in the study Exclusion Criteria: 1. Presence of chest wall deformity 2. Presence of pacemaker/defibrillator 3. Pregnancy 4. Presence of acute respiratory tract infection and/or pneumonia 5. Suspicion of underlying hemidiaphragmatic paresis (defined as elevation of one hemidiaphragm \>2.5 cm compared to the other on chest radiography) 6. Known history of inflammatory rheumatologic or neuromuscular disease that may affect the mechanics of the diaphragm (cerebrovascular accident, spinal cord injury, epilepsy, peripheral neuropathy, and muscle diseases, etc.) 7. Suspected paraneoplastic or myopathic syndromes and/or use of medications known to alter muscle structure and/or function, including oral corticosteroids 8. History of recent thoracic and/or abdominal surgery 9. History of COPD exacerbation within the last 4 weeks 10. COPD disease is accompanied by bronchial asthma, interstitial lung diseases, lung neoplasia, metabolic diseases (diabetes mellitus, uremia and liver failure) 11. Body mass index greater than 40 12. Presence of contraindications for exercise program (uncontrolled atrial/ventricular arrhythmia, resting systolic blood pressure ≥ 200 mm Hg or diastolic blood pressure ≥ 110 mm Hg, severe aortic stenosis, recent history of embolism, decompensated heart failure, cardiac ischemic event within the last four weeks) 13. Presence of systemic disease and/or musculoskeletal disease that may prevent exercise
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06714721 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Obstructive Pulmonary Disease (COPD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06714721 currently recruiting?
Yes, NCT06714721 is actively recruiting participants. Contact the research team at kurtais@gmail.com for enrollment information.
Where is the NCT06714721 trial being conducted?
This trial is being conducted at Ankara, Turkey (Türkiye).
Who is sponsoring the NCT06714721 clinical trial?
NCT06714721 is sponsored by Ankara University. The trial plans to enroll 66 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.